New Alzheimer's drug will make faster access to scans necessary 

The HSE is examining how to boost access to scans for Alzheimer’s disease so patients can take advantage of a new American drug, a leading advocate has said.

The HSE is examining how to boost access to scans for Alzheimer’s disease so patients can take advantage of a new American drug, a leading advocate has said.

However the treatment, approved by the American Food and Drug Administration for use there, is unlikely to reach Ireland before 2022. It is under review by the European Medicines Agency.